This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms 
Introduction
The magnitude of cardiac damage resultant from ischemic-reperfusion injury during cardiac surgery is inversely related to both early and long-term survival. 1 Accordingly, there is significant interest in reducing ischemic-reperfusion injury to improve postoperative outcomes. To this end, both sevoflurane and propofol have demonstrated utility for preoperative conditioning. [2] [3] [4] Sevoflurane is thought to reduce reperfusion injury by attenuating cellular Ca 2+ overload, 5 whereas propofol exerts antioxidant effects that decrease oxidative myocardial injury secondary to the generation of reactive oxygen species. 6 Yet, it is unclear whether one of these agents is superior for preventing damage during cardiac surgery. 7 A majority of previous studies examining the protective conditioning effects of sevoflurane and propofol were conducted in heterogeneous populations (e.g., different baseline cardiac diseases, different operative techniques) with several confounding morbidities (e.g. inclusion of patients with diabetes or previous ischemic episodes). 8 Patients with organic mitral regurgitation in the absence of coronary disease may represent an ideal substratum for investigating the utility of potential conditioning agents. Moreover, minimally invasive mitral valve repair is a procedure associated with prolonged durations of ischemia 9 and significant ischemic-reperfusion injury, such that strategies for decreasing troponin release in this context are needed.
The aim of this study was to determine whether propofol or sevoflurane anesthesia confers superior cardioprotection in patients undergoing isolated minimally invasive mitral valve repair.
Methods

Ethical approval
This trial was registered with ClinicalTrials.gov (NCT02551328). The study protocol was approved by the Area Vasta Toscana Ethics Committee (reference CEAVNO no. 452/14) and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to study participation. All authors had access to the study data and reviewed and approved the final manuscript.
Trial design
The MINI-SEVO trial was a single-center, single blind, randomized controlled trial.
Participants were randomly allocated to propofol or sevoflurane anesthetic conditioning regimens using a 1:1 ratio.
Participants
Adults (age >18 years) undergoing elective isolated minimally invasive mitral valve repair for degenerative disease were eligible for study participation. The exclusion criteria were secondary mitral regurgitation, previously treated coronary artery disease such as a history of coronary stenting or coronary artery bypass grafting, diabetes mellitus, chronic renal failure requiring dialysis, atrial fibrillation (AF), or documented allergy to either propofol or sevoflurane. The study was conducted at G. Pasquinucci Heart Hospital, Fondazione Toscana G. Monasterio, a specialized regional cardiac surgery center in Italy.
Intervention
Beta-adrenergic antagonists and other relevant medications were continued until the morning of surgery in all patients. In the operating room, patients were monitored with 5-lead electrocardiography, left radial artery catheter, capnography, pulse oximetry, blood findings, and rectal/urine bladder temperatures. Transesophageal echocardiography was used in all patients.
In the group randomized to sevoflurane (Sevoflurane®, Abbott), anesthesia was induced with intravenous sufentanil (0. Anesthesia was maintained with sevoflurane at a minimum end-tidal concentration of at least 1 minimal alveolar concentration (MAC) throughout the entire procedure, including cardiopulmonary bypass (CPB) and endovenous sufentanil (0.01-0.02 mcg kg -1 min). During CPB, sevoflurane was administered in the oxygenator circuit through a calibrated vaporizer and MAC was measured at the outlet of the oxygenator of the extracorporeal circulation.
Patients of this group received no propofol: neither during surgery, nor during ICU stay.
In the group randomized to propofol (Diprivan, Astra-Zeneca, Stockholm, Sweden), anesthesia was induced with intravenous sufentanil (0.5-1 mcg kg -1 ) and propofol (2 mg-kg -1 ). Tracheal intubation was facilitated with intravenous rocuronium (0.6-1 mg kg -1 ).
Anesthesia was maintained with propofol (0.1 -0.5 mg kg -1 min) and sufentanil (0.01-0.02 mcg kg -1 min). No volatile anesthetic was used at any time during the procedure.
In both groups, depth of anesthesia was monitored with bispectral index (BIS XP ®, Aspect
Medical System, Newton, MA); the dosage of propofol and sevoflurane (within the above ranges) was titrated to maintain BIS values from 40 to 60.
Postoperatively, the inspired oxygen fraction was set at 0. mmHg and bleeding from chest tubes was < 1 mL/kg, sedation was stopped.
Extubation was then performed if patients' cardio-circulatory, respiratory (partial pressure of oxygen/FiO2 < 250, respiratory rate > 25/min, FiO2 40-50%) and neurological criteria were within range. Criteria for intensive care discharge were: hemodynamic stability with no inotropic support, spontaneous breathing and clear neurological status.
Surgical technique
The surgical approach used in this study has been previously described. 10 Briefly, a central aortic cannulation was performed and venous drainage was achieved by percutaneous cannulation of the right femoral vein. A small 5-cm incision was made at the level of the 4 th intercostal space. Two ports were used for camera insertion, cardiotomy venting, CO2
insufflation, and other pericardial stay sutures. After CPB, the aorta was clamped under direct supervision and cold crystalloid cardioplegia (CUSTODIOL® Bretschneider's HTKSolution, DR. FRANZ KÖHLER CHEMIE, Bensheim, Germany) with single antegrade delivery (25 ml kg -1 ) was used. The mitral valve was then exposed through a left para-septal atriotomy. Mitral repair was performed in accordance with the mechanism of regurgitation.
Outcomes
The primary outcome was myocardial injury as assessed by serum cardiac troponin I (cTnI) in blood samples collected preoperatively and at 1, 6, 12, 24, and 72 h after the end of the 
Randomization and blinding
Random allocations were generated by computer software. Treatment allocations were (a) blocked with varying block sizes to ensure approximate balance in the number of participants allocated to each group; (b) generated prior to the study; and (c) accessed using a secure, internet-based randomization system to guarantee concealment until each participant's identity and eligibility was confirmed and securely documented. A designated research nurse who was not involved in data collection performed patient randomization after acquiring written consent and as close as possible to the operation date. Participants were blinded to the intervention given that all conditioning was performed in the operatory theatre and there were no visible signs of the anesthetic conditioning regimens. Operating staffs were not blinded to treatment given the nature of the study.
Statistical analysis
The assumption of normality of each variable distribution was tested with the Shapiro- Model validity was checked and poor fit was addressed by exploring transformations.
Outcomes analyzed on a logarithmic scale were transformed back to the original scale after the analysis and results were presented as geometric mean ratios (GMRs).
Likelihood ratio tests were used to determine statistical significance. The effect of cross clamp time on cTnI release was explored with a Pearson's correlation analysis. No subgroup analyses were planned. The trial was not powered to detect differences in clinical outcomes; therefore, frequencies are tabulated descriptively. The threshold for statistical significance was p < 0.05. All analyses were performed using R-project (R Core Team 2013, Vienna, Austria; http://www.R-project.org/) (packages: 'stat', 'graph', 'ggplot2').
Results
Patient recruitment
Between March 2015 and December 2016, 225 patients were assessed for study inclusion; of these, 160 did not meet the inclusion/exclusion criteria and were excluded (see CONSORT diagram / figure 1. After randomization, 3 patients were excluded due to concomitant tricuspid surgery and AF ablation. There were 2 protocol violations: 1 patient allocated to the propofol group received sevoflurane and 1 patient allocated to the sevoflurane group received propofol. One patient in the sevoflurane group was converted to stenotomy and underwent mitral valve replacement for a failed repair. These patients were included in the intention-totreat population. Therefore, 62 participants were included in the per-protocol analysis ( Figure   1 ).
Baseline data
The mean age of the population was 64.7 ± 11.9 years and 28 of 62 patients (45.1%) were male. Patients allocated to propofol group were older than those allocated to the sevoflurane group (68.3 ± 9.5 years vs. 60.7 ± 12.5 years, respectively). The median Logistic European System for Cardiac Operative Risk Evaluation score was 3.7 (IQR, 5). Other baseline characteristics and mitral valve regurgitation values are summarized in Table 1 .
Operative data
Total CPB times and cross clamp times were similar between the propofol and sevoflurane Table 2 .
Postoperative outcomes
Time courses of cTnI values are shown in Figure 2A . Preoperative concentrations of cTnI were undetectable in both treatment groups (< 0.01 ng ml -1 ). Concentrations of cTnI were increased postoperatively and peaked at 6 h after surgery; these values were, on average, 8% lower in the propofol group compared to the sevoflurane group, but this difference was not statistically significant (GMR 0.92; 95% confidence interval [CI] 0.63-1.27, p = 0.62). Peak cTnI release occurring at 6 and 12 h after surgery was positively correlated with cross clamp time in both groups (p < 0.001) (Fig. 3, 4) . vs. 8 days (IQR, 2)) ( Table 3) . Mean pre-and postoperative left ventricle ejection fractions were 58.2 ± 6.8% and 50 ± 5.7% in the propofol group and 59 ± 7.9% and 50 ± 10.3% in the sevoflurane group, respectively.
Postoperative complications
There were no in-hospital deaths. One patient in the sevoflurane group was re-operated for bleeding but conversion to sternotomy was not necessary. Other event rates were similar between the 2 treatment groups (Table 3 ). All patients were discharged with no or negligible residual mitral regurgitation. No unexpected serious adverse events occurred.
Discussion
To the best of our knowledge, this is the first study to compare the effects of propofol and sevoflurane as conditioning agents in patients undergoing isolated minimally invasive mitral valve repair. Our study found that both conditioning regimens were associated with similar degrees of myocardial injury. Bignami and colleagues compared propofol and sevoflurane in terms of cardiac troponin release in patients with coronary disease undergoing mitral surgery, 12 and Landoni and colleagues investigated the effects of desflurane versus propofol in patients undergoing mitral surgery 13 ; however, neither study clarified whether volatile anesthesia was superior to intravenous anesthesia for mitral valve repair. In the latter study, subjects with concomitant coronary disease were not excluded, and moreover desflurane was used only as preconditioning agent for 30 minutes. The vast majority of previous studies on anesthetic conditioning were conducted in the context of coronary bypass grafting, and very few investigations have focused on isolated valve repair. 8 Additionally, investigations performed in patients with coronary disease failed to control for several confounding factors including diabetes and related medication use, previous angina, hibernating myocardium, coronary micro-embolization, no-reflow, and hypercholesterolemia. 14 Accordingly, these studies have yielded inconsistent results.
We believe that patients with isolated valve disease such as degenerative mitral valve disease provide an ideal scenario for testing the abilities of potential conditioning agents to prevent myocardial damage. Furthermore, organic mitral valve disease has a lower association with coronary disease than aortic valve disease, which is associated with hypertension, diabetes, and dyslipidemia. 15 It can be argued that different forms of anesthetic conditioning (e.g., remote ischemic, volatile, etc.) do not add additional protection against cardioplegic arrest in the context of bypass grafting, since patients with coronary disease may already be naturally preconditioned.
In the present study, we were unable to demonstrate superiority of one anesthetic regimen over another for decreasing cTnI release in patients who underwent isolated mitral valve repair; patients in the propofol group tended to have lower cTnI release, but this difference was not statistically significant. Moreover, postoperative left ventricular function assessed between days 4 and 6 was similar between the 2 treatment groups. Rather, we uncovered a positive correlation between cross clamp time and peak troponin release in both groups.
Minimally invasive surgery may require longer operation times 9 and thus an increased likelihood of ischemic-reperfusion injury in cardiac settings, accounting for an association between operation time and troponin release.
With regard to secondary outcomes, mechanical ventilation time was significantly shorter in the sevoflurane group than in the propofol group. The duration of mechanical ventilation is influenced by the sedation regimen used in the intensive care unit; in this study, the suspension of continuous infusion of hypnotic agents before arrival in the intensive care unit in the sevoflurane group was likely the main cause of early extubation.
An important strength of the present study was that we did not include patients with combined coronary disease, ensuring no previous exposure to angina or other natural ischemic preconditioning. Additionally, we excluded diabetic patients so as to avoid the possible influence of diabetic medication. This study was conducted in a high-volume mitral reference center with surgeons performing more than 50 mitral repairs per year, so that there was no learning curve effect on the present results. Finally, pain stimuli may elicit preconditioning as a confounding factor, such that the use of a minimally invasive procedure in this study reduced the contribution of nociceptive components. 16 This study had some limitations. First, this research was a proof-of-concept analysis that was primarily based on troponin release. For practical reasons, participants but not physicians and medical staff were blinded to treatment group assignments. Second, this trial did not include a third arm to examine synergy between sevoflurane and propofol, nor were the dosedependent effects of propofol and sevoflurane 6 investigated; instead, our study design corresponded with routine anesthetic practice and evaluated potential differences between 2 standard regimens. Third, our trial included relatively low-risk patients, which may limit its generalizability to larger patient populations. Notably, we did not follow-up patients in our study; however, only weak evidence supports the idea that anesthetic conditioning has effects on late post-surgical outcomes. 8 Another important consideration is that in the propofol group, propofol infusion was continued in the intensive care unit and may have provided post-conditioning, whereas sevoflurane was not. There is some evidence that the preconditioning effect of sevoflurane is enhanced when treatment is maintained during the first 6 h after surgery, 17 yet the most uniform cardioprotective effects are seen when sevoflurane is administered for the duration of the procedure. 18 Finally, sufentanil was used in both groups; opioids produce cardioprotection against ischemia-reperfusion injury in rodents in a manner potentially related to adenosine receptor cross-talk. 19 Future studies should address these important points in order to better inform the utility of different anesthetic preconditioning regimens in cardiac surgery.
Conclusions
Propofol and sevoflurane anesthesia were associated with similar degrees of myocardial injury in patients undergoing minimally invasive mitral valve repair for degenerative disease.
Notably, injury was directly related to the duration of cardioplegic arrest regardless of the preconditioning regimen.
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